Company intelligence / Profile preview
Mapp Biopharmaceutical
San Diego, California, United Statesmappbio.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Mapp develops antibody therapeutics for viral hemorrhagic fevers, with ZMapp (Ebola) in Phase-3 and Marburg treatment showing >80% efficacy in non-human primates. Recent collaborations include BARDA-funded Marburg therapeutic development and human trials for Nipah antibody.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Monoclonal antibodiesAntibody fusion proteins
- Industry
- Biotech
02
Drug pipeline
18 assets17 more assets in the full pipeline.
Request access →03
Partnerships
BARDA(HHS)ProBioGen(Germany)KBP(Reynolds American)
Beyond the preview
Go deeper on Mapp Biopharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mapp Biopharmaceutical.